Which endpoint showed a 51% risk reduction in the AGENT IDE trial?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Practice for Clinical Training 1 (CT1) Day 4 Exam. Enhance your skills with a range of questions designed to test your clinical knowledge. Each question features detailed explanations to help you succeed.

Multiple Choice

Which endpoint showed a 51% risk reduction in the AGENT IDE trial?

Explanation:
The endpoint that demonstrated a 51% risk reduction in the AGENT IDE trial is related to Target Lesion Revascularization (TLR). TLR measures the need for repeat revascularization procedures on the same target lesion due to symptoms or significant ischemia, indicating the durability of the initial treatment. A 51% risk reduction in TLR suggests that the treatment being assessed in the AGENT IDE trial significantly lowers the likelihood of patients requiring additional interventions, which speaks to the effectiveness of the therapy in maintaining long-term results for patients with cardiovascular conditions. The other endpoints listed, such as TVMI (target vessel myocardial infarction) and TVR (target vessel revascularization), may not have shown such a substantial reduction or could have been measured differently in the context of the AGENT IDE trial. Thus, TLR is recognized as the specific endpoint indicating substantial improvement based on the trial results.

The endpoint that demonstrated a 51% risk reduction in the AGENT IDE trial is related to Target Lesion Revascularization (TLR). TLR measures the need for repeat revascularization procedures on the same target lesion due to symptoms or significant ischemia, indicating the durability of the initial treatment. A 51% risk reduction in TLR suggests that the treatment being assessed in the AGENT IDE trial significantly lowers the likelihood of patients requiring additional interventions, which speaks to the effectiveness of the therapy in maintaining long-term results for patients with cardiovascular conditions.

The other endpoints listed, such as TVMI (target vessel myocardial infarction) and TVR (target vessel revascularization), may not have shown such a substantial reduction or could have been measured differently in the context of the AGENT IDE trial. Thus, TLR is recognized as the specific endpoint indicating substantial improvement based on the trial results.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy